Emmett and colleagues evaluate the frequency, magnitude and clinical significance of early prostate-specific membrane antigen (PSMA) upregulation in patients with metastatic castrate-resistant prostate cancer treated with enzalutamide with or without 177Lu-PSMA-617.
- Louise Emmett
- Mina Swiha
- Ian D. Davis
